Detalhe da pesquisa
1.
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
Breast Cancer Res
; 25(1): 67, 2023 06 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37308971
2.
ATM Variant as a Cause of Hereditary Cutaneous Melanoma in a Spanish Family: Case Report.
Case Rep Oncol
; 17(1): 386-391, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38415270
3.
Significant Decrease in Annual Cancer Diagnoses in Spain during the COVID-19 Pandemic: A Real-Data Study.
Cancers (Basel)
; 13(13)2021 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34203185
4.
Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients.
Eur J Cancer
; 144: 224-231, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33373867
5.
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Front Oncol
; 9: 1178, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31750258
6.
Case Report: Propranolol increases the therapeutic response to temozolomide in a patient with metastatic paraganglioma.
F1000Res
; 6: 2087, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29527294